1032825-19-6

Basic information

• Product Name: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)Methyl Methanesulfonate
• Synonyms: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)Methyl Methanesulfonate
• CAS NO: 1032825-19-6
• Molecular Formula: C₁₂H₂₁N₃O₄S
• Molecular Weight: 303.37784
• Mol File: 1032825-19-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)Methyl Methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)Methyl Methanesulfonate(1032825-19-6)
• EPA Substance Registry System: (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)Methyl Methanesulfonate(1032825-19-6)

Safety Data

• Hazardous Substances Data: 1032825-19-6(Hazardous Substances Data)

Usage

General Description

"(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)Methyl Methanesulfonate" is a chemical compound with the molecular formula C13H22N4O4S. It is a methanesulfonate ester of piperidine-based compound with an oxadiazole functional group. (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)Methyl Methanesulfonate is often used in pharmaceutical research and development as a potential drug candidate. It may have applications in the treatment of various medical conditions, although more research is needed to determine its specific uses and potential benefits. As with any chemical compound, proper handling and safety precautions should be taken when working with "(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)Methyl Methanesulfonate".

Upstream product

• 1032824-91-1 4-(hydroxymethyl) piperidine-1-carbonitrile 
• 6457-49-4 4-piperidinemethanol 
• 1032824-92-2 (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methanol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1032823-75-8 ((5-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-2-[4-(methylsulfonyl)phenyl]pyridine)) 
• 1351345-51-1 ((3R,4S)-4-(2,4-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-51-6 (3R,4S)-1-{5-[l-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylamine 
• 1351345-52-2 [(3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351338-52-7 ((3R,4S)-4-(4-chloro-2-fluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)amine 
• 1351345-53-3 ((3R,4S)-4-(4-chloro-2-fluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-57-2 (3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-54-4 ((3R,4S)-4-(2,5-difluorophenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1351338-59-4 (3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-ylamine p-toluenesulfonate 
• 1351345-55-5 [(3R,4S)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methylpyrimidin-2-yl}-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester 
• 1351343-45-7 ((3R,4S)-4-(2,5-difluoro-phenyl)-1-{5-[1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-ylmethoxy]-4-methoxy-pyrimidin-2-yl}pyrrolidin-3-yl)carbamic acid tert-butyl ester 
• 1032825-91-4 2-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-5-[2-methyl-4-(methylthio)phenyl]pyrazine 
• 1032825-74-3 2-[2-fluoro-4-(methylthio)phenyl]-5-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]pyridine 
• 1032825-69-6 5-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-2-[4-(methylthio)phenyl]pyridine 

Relevant articles and documents

CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.